Abstract:Background: Influenza is a single-stranded RNA virus that is highly contagious and infects millions of people in the U.S. annually. Due to complications, approximately 959,000 people were hospitalized and another 79,400 people died during the 2017-2018 flu season. While the best methods of prevention continue to be vaccination and hygiene, antiviral treatments may help reduce symptoms for those who are infected. Until recently, the only antiviral drugs in use have been the neuraminidase inhibitors: oseltamivir, zanamivir, and peramivir. Objective: We reviewed novel drug targets that can be used in the treatment of influenza, particularly in the case of neuraminidase inhibitor-resistant strains that may emerge. Results: More recently, a drug with a new mechanism of action has been approved. Baloxavir marboxil inhibits the influenza cap-dependent endonuclease that is needed for the virus to initiate replication within the host cell. This endonuclease target is within the polymerase acid (PA) subunit of RNA polymerase. Since the RNA-dependent RNA polymerase consists of two other subunits, polymerase basic 1 and 2, RNA polymerase has several targets that prevent viral replication. Other targets still under investigation include viral kinases, endocytosis, and viral fusion. Conclusion: Due to the possibility of viral mutations and resistance, it is important to have antivirals with different mechanisms available, especially in the case of a new pandemic strain. Several novel antivirals are within various stages of development and may represent new classes of treatments that can reduce symptoms and complications in those patients who may be at higher risk.

Current and novel antiviral strategies for influenza infection

Research Progress on Drug-Resistance of Influenza Virus to Neuraminidase Inhibitors

Emerging antiviral therapies and drugs for the treatment of influenza

Antiviral strategies against influenza virus: towards new therapeutic approaches

Potential Role of Endonuclease Inhibition and Other Targets in the Treatment of Influenza

Contemporary medicinal chemistry strategies for the discovery and optimization of influenza inhibitors targeting vRNP constituent proteins

Progress Of Small Molecular Inhibitors In The Development Of Anti-Influenza Virus Agents

Potential targets and their relevant inhibitors in anti-influenza fields.

Recent Progress of Novel Anti-Influenza Entry Inhibitors

Antivirals Targeting the Surface Glycoproteins of Influenza Virus: Mechanisms of Action and Resistance

New small-molecule drug design strategies for fighting resistant influenza A.

Influenza Viruses: Harnessing the Crucial Role of the M2 Ion-Channel and Neuraminidase toward Inhibitor Design

Approaches for discovery of small-molecular antivirals targeting to influenza A virus PB2 subunit

Viral RNA Polymerase: A Promising Antiviral Target for Influenza A Virus

Contemporary Medicinal Chemistry Strategies for the Discovery and Optimization of Infiuenza Inhibitors Targeting Vrnp Constituent Proteins

Recent advances in neuraminidase inhibitor development as anti-influenza drugs.

Recent advances in the structure-based design of neuraminidase inhibitors as antiinfluenza agents.

Antiviral options and therapeutics against influenza: history, latest developments and future prospects

Treating influenza with neuraminidase inhibitors: an update of the literature

Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives

Retracted and republished from: "The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs"